Case Report

Trazodone induced urinary incontinence in woman at menopause period: A case report

Pezhman Hadinezhad (M.D)¹, Seyyed Hamzeh Hosseini (M.D)*²

¹Psychiatry Resident, Department of Psychiatry, Mazandaran University of Medical Sciences, Sari, Iran.
²Professor of Psychiatry, Department of Psychiatry, Psychiatry and Behavioral Sciences Research Center, Faculty member of Mazandaran University of Medical Sciences, Sari, Iran.

Abstract

Trazodone is a weak inhibitor of serotonin reuptake and a potent antagonist of serotonin 5HT2A and 5HT2C receptors. Urinary incontinence is a rare side effect of anti-depressant drugs. Side effects of antidepressants can cause delay in treatment of patient and ultimately non-compliance in patients who take this medicinal drug. Here we present a case of trazodone induced urinary incontinence in a woman at menopause period. The patient was a retired woman with 63 years old. She reported a history of bladder prolapse and history of consumption of quetiapine and propranolol. But the patient had no history of other somatic illnesses, drug and urinary incontinence before administering the medicinal drug. Psychiatrist prescribed trazodone with dose of 50 mg, orally per day when appearance of the depression, anxiety and insomnia. But, the patient suddenly suffered from urinary incontinence, despite this situation the patient had continued taking the drug for three days. Due to the uncertainty of the above complications patient, was forced to discontinue the drug and following drug discontinuation the side effect disappeared. After the improvement of the urine incontinence and full recovery, re-treatment was began with the same dose of 50 mg trazodone for the patient, but immediately after drug administration to the patient, urinary incontinence appeared once again. Trazodone can be considered as important factor to cause urinary incontinence. Therefore, this issue should be considered whenever this pharmaceutical drug is prescribed.

Keywords: Trazodone, Urinary incontinence, Menopause

* Corresponding Author: Hosseini SH (M.D), E-mail: hosseinish20@gmail.com

Received 1 Jul 2017  Revised 23 Oct 2017  Accepted 11 Dec 2017

Pezhman Hadinezhad (https://orcid.org/0000-0002-8746-198X), Seyyed Hamzeh Hosseini (https://orcid.org/0000-0001-7655-8869)